MANY MINDEDEarly Pediatric Cancer Therapy Shows Promise in Single Case
A 3-year-old boy with hepatoblastoma—a malignant liver cancer that had metastasized to his lungs and bones—achieved complete tumor regression after two doses of GPC3-CAR CAR T cell therapy. His initial liver tumor measured 11.2 cm × 9.6 cm × 7.1 cm and showed partial response after the first infusion, with declining alpha-fetoprotein levels and reduced tumor size on CT scans. Following a second infusion eight weeks later, follow-up CT scans revealed no remaining disease signs, only residual scarring. The patient remained disease-free at 12 months post-treatment.
The therapy uses the patient’s own T cells engineered to target glypican-3 (GPC3), with added interleukin-15 and interleukin-21 genes to enhance tumor-killing and longevity. This approach represents a potential pathway to more effective, lower-cost pediatric cancer treatments, as current therapies for metastatic hepatoblastoma are often complex, expensive, and limited by severe side effects.
This case moves abundance for children with advanced hepatoblastoma by demonstrating that highly targeted immunotherapies could achieve durable remission without prolonged chemotherapy. However, it remains a single patient case in an early-phase clinical trial (CARE study), with effectiveness and safety unproven for broader populations. The therapy’s scalability and long-term outcomes require further assessment in larger trials before it can address the global need for accessible pediatric cancer care.
Source: ScienceAlert